Navigation Links
Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
Date:6/23/2011

SKILLMAN, N.J., June 23, 2011 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced new observational study results showing that use of ConvaTec Moldable Technology™ Skin Barriers helped to maintain skin integrity and improve peristomal skin issues in stoma patients. The preliminary study results were presented at the 11th Congress of the European Council of Enterostomal Therapy (ECET) in Bologna, Italy.

"Peristomal skin integrity plays an important role in stoma management, and the selection of a skin barrier is the first line of defense in maintaining healthy skin," said lead investigator Daniele Chaumier, ET Nurse, Hopital Tenon, Paris, France.  "The preliminary results observed in this study, conducted in routine care, show that utilizing this unique skin barrier technology can improve peristomal skin issues and prevent their occurrence."

The observational, prospective study titled OSMOSE* evaluated the progression of peristomal skin conditions in stoma patients using ConvaTec Moldable Technology™ Skin Barriers over a two month period, involving more than 100 active centers in France.  The study included two arms: 1) patients using ConvaTec Moldable Technology™ Skin Barriers as their first system after surgery and 2) patients using ConvaTec Moldable Technology™ Skin Barriers as a replacement for another device due to a reported peristomal skin issue. The level of patient satisfaction and the potential impact on quality of life were also assessed.

Both sets of patients in the study were evaluated over the test period by clinicians using the SACS™ Instrument, a content-validated instrument to assess and classify peristomal skin lesions by type and location in relation to the stoma.

More than 800 colostomy and ileostomy patients were enrolled and data for more than 700 patients were analyzed. Among patients in the first arm who completed the study (N=305), most of whom had normal skin at baseline, skin integrity was maintained or improved in nearly all patients (95 percent).  Among patients in the second arm who completed the study (N=140), all of whom had skin issues at baseline, nearly all patients (90 percent) were classified as having normal skin or improved pre-existing lesions by the end of the study period.

Participants who completed the final product evaluation of the study also reported very high levels of satisfaction with ConvaTec Moldable Technology™ Skin Barriers, with both groups combined providing ratings of "excellent" or "good" in excess of 80 percent across all criteria including comfort, ease of molding, ease of application and removal, level of confidence and overall evaluation.

ConvaTec Moldable Technology™ Skin Barriers with Rebounding Memory Technology™ are the only skin barriers with a patented** tri-laminate construction that actively adjusts to the shape and contours of the stoma. ConvaTec Moldable Technology™ Skin Barriers are supported by extensive clinical experience demonstrating their ability to prevent leaks and protect the peristomal skin.(1) (2)

About Peristomal Skin Disorders

Peristomal skin disorders and lesions are common complications affecting people living with an ostomy.(3) While estimates of the incidence of peristomal skin disorders vary, a Danish study showed that these complications can appear in 45 percent of patients living with a stoma.(3)  Research also indicates that peristomal skin disorders negatively impact quality of life, including the psychological and social behavior of patients.(4)(5)

About the SACS™ Instrument

The SACS™ Instrument was developed to help establish a standard universal scale for assessing and classifying peristomal lesions by type of lesion (L) and the topographical location of skin breakdown (T).  Initially developed by a consensus of Italian healthcare professionals (the Studio Alterazioni Cutanee Stoma, or Study on Peristomal Skin Lesions, study group), the instrument was published in Ostomy Wound Management in 2007; following which it was endorsed by the Italian ET association (AIOSS) and adopted in Italy.  The instrument has been subsequently content validated in the U.S.(6)

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. For more information, please visit www.convatec.com.

ConvaTec Moldable Technology, SACS and Rebounding Memory Technology are trademarks of ConvaTec Inc.

*OSMOSE Study: An evaluation of the peristomal skin condition in patients using ConvaTec Moldable Technology™ Skin Barriers – Preliminary Results.  Poster presented at the 11th Congress of Enterostomal Therapy (ECET in Bologna, Italy; June12-15, 2011.

** U.S. Patent No. 6,840,924 B2

© 2011 ConvaTec Inc.

SC-000248-MM



(1) Scott V, Raasch D, Kennedy G, Heise C. Prospective assessment and classification of stoma related skin disorders. Poster presented at: 41st Annual Wound Ostomy and Continence Nurses Society Conference; June 6-10, 2009; Orlando, Florida.

(2) Hoeflok J, Guy D, Allen S, St-Cry D. A prospective multicenter evaluation of a moldable stoma skin barrier. Ostomy Wound Manage. 2009;55(5):62-69.

(3) Herlufsen P, Olsen AG, Carlsen B et al. Study of peristomal skin disorders in patients with permanent stomas. Br J Nurs. 2006 Sep 14-27;15(16):854-62.

(4) Brown H, Randle J. Living with a stoma: a review of the literature. J Clin Nurs 2005; 14:74-81.

(5) Berg K, Seidler H. Randomized crossover comparison of adhesively coupled colostomy pouching systems. Ostomy Wound Management 2005; 51: 30-36

(6) Beitz J, Ho M. Content validation of an ostomy algorithm with peristomal skin assessment (SACS) instrument. Poster presented at the 2010 Joint Conference of The Wound, Ostomy, and Continence Nurses Society and World Council of Enterostomal Therapists; June 12-16, 2010; Phoenix, AZ.


'/>"/>
SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SAO PAULO , March 23, 2017 ... accordance with article 157, paragraph 4 of Law 6,404/76 ... Commission (CVM), hereby informs its shareholders and the market ... jointly with its subsidiary Centro de Diagnosticos por Imagem ... acquisition of 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" ...
(Date:3/23/2017)...  A new genetic test has been discovered ... who carry HLA-B*15:02 and who are ... deadly side effect of certain medications used to ... HLA-B*15:02 is strongly associated with life-threatening severe ... toxic epidermal necrolysis in patients treated with carbamazepine ...
(Date:3/23/2017)... 23, 2017 On Wednesday, ... trading session at 5,821.64, up 0.48%; the Dow ... at 20,661.30; and the S&P 500 closed at ... as six out of nine sectors ended the ... reports coverage on the following Medical Instruments & ...
Breaking Medicine Technology:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s Patriot Award. ... the presentation, General Thomas thanked Task Force Dagger Foundation for its significant and ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to host Shriners and ... will be located in the Main West Entrance of The Boulevard (in front of ... appointment is necessary and each child with a parent or guardian will be photographed ...
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a call to ... the creation of published author, Desiree M Webb, a registered nurse, minister of music, ... happily married to her husband, Paul, for over twenty-nine years. Desiree enjoys writing, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
Breaking Medicine News(10 mins):